Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Novo Nordisk stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share on $11.92 billion in fourth-quarter sales. Please watch the video at ...

Digital health company Liva Healthcare has acquired UK-based Momenta, a provider of digital, virtual, and in-person healthy ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported ... competition and continued pricing pressure within Diabetes and Obesity care" market. However, Jørgensen said the lower ...

Europe's largest pharmaceutical firm, Novo Nordisk, reported fourth-quarter ... in 2024 to 128.3bn DKK (€17.2bn), with sales in diabetes and obesity care rising by 26%, mainly driven by GLP ...

Obesity drug maker Novo Nordisk has forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good ...

Trial 1) 1 hour of glucagon infusion (GlucaGen, Novo Nordisk) at 6 ng/kg/min ... Animal protocols were approved by the University of Guelph Animal Care Committee and followed guidelines established by ...

The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug, showed a reduced risk of kidney failure. Experts explain how the drug ...